Nerandomilast is a medication being tested to see if it can help people with certain lung problems that are related to autoimmune diseases. These diseases cause the body’s immune system to attack its own tissues, and in this case, it affects the lungs. The trial is looking at how well this medication can reduce lung damage over a period of 26 weeks. The goal is to see if nerandomilast can improve lung health by reducing the extent of lung involvement, which is measured using special imaging techniques.

Nintedanib is another medication that is part of this trial. It is already known to help with certain lung conditions by slowing down the worsening of lung function. In this study, it is used to see if it can work alongside nerandomilast to provide better outcomes for patients with lung issues related to autoimmune diseases. The trial will observe how nintedanib affects the lungs when used in combination with other treatments over the 26-week period.

Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) – This condition involves a group of autoimmune diseases that affect the connective tissues and can lead to inflammation and scarring of the lungs, known as interstitial lung disease. The disease progresses as the immune system mistakenly attacks the body’s own tissues, causing inflammation in the lungs. Over time, this inflammation can lead to fibrosis, or thickening and scarring of lung tissue, which can impair lung function. Patients may experience symptoms such as shortness of breath, a persistent dry cough, and fatigue. The progression of lung involvement can vary, with some individuals experiencing a slow progression while others may have a more rapid decline in lung function. The extent of lung damage can be assessed using imaging techniques like high-resolution computed tomography.